The positive feedback from the FDA regarding Multikine's confirmatory Registration Study is a significant milestone for CEL-SCI, likely leading to increased investor confidence and potential stock price appreciation in the short term. The FDA's acceptance of the study design and pre-surgical patient selection criteria, along with the demonstrated survival benefit in previous studies, positions Multikine as a promising addition to the standard of care for advanced primary head and neck cancer, further driving investor optimism.